CN1301168A - 治疗性二核苷酸和衍生物 - Google Patents

治疗性二核苷酸和衍生物 Download PDF

Info

Publication number
CN1301168A
CN1301168A CN99806423A CN99806423A CN1301168A CN 1301168 A CN1301168 A CN 1301168A CN 99806423 A CN99806423 A CN 99806423A CN 99806423 A CN99806423 A CN 99806423A CN 1301168 A CN1301168 A CN 1301168A
Authority
CN
China
Prior art keywords
formula
chemical compound
compound described
ester
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99806423A
Other languages
English (en)
Chinese (zh)
Inventor
B·R·叶克
W·彭德格斯特
J·L·里德乌
M·皮彻
R·C·鲍彻
M·J·斯塔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Inspire Pharmaceuticals Inc
Original Assignee
University of North Carolina at Chapel Hill
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Inspire Pharmaceuticals Inc filed Critical University of North Carolina at Chapel Hill
Publication of CN1301168A publication Critical patent/CN1301168A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN99806423A 1998-05-22 1999-05-19 治疗性二核苷酸和衍生物 Pending CN1301168A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8654398P 1998-05-22 1998-05-22
US60/086,543 1998-05-22

Publications (1)

Publication Number Publication Date
CN1301168A true CN1301168A (zh) 2001-06-27

Family

ID=22199276

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99806423A Pending CN1301168A (zh) 1998-05-22 1999-05-19 治疗性二核苷酸和衍生物

Country Status (9)

Country Link
US (1) US6323187B1 (enExample)
EP (1) EP1087777B1 (enExample)
JP (1) JP4633927B2 (enExample)
CN (1) CN1301168A (enExample)
AT (1) ATE232733T1 (enExample)
AU (1) AU746750B2 (enExample)
CA (1) CA2332540A1 (enExample)
DE (1) DE69905464T2 (enExample)
WO (1) WO1999061012A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923143A (zh) * 2014-04-10 2014-07-16 江西科技师范大学 一种合成双核苷四磷酸以及p2,p3-（双卤代）亚甲基双核苷四磷酸的方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
DE69822482T2 (de) 1997-07-25 2005-03-03 Inspire Pharmaceuticals, Inc. Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
KR20010099865A (ko) * 1998-12-22 2001-11-09 프란시스 제이 메이어 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
DE60006814T2 (de) * 1999-06-30 2004-05-19 Yamasa Corp., Choshi Dinucleotid-kristalle
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
BR0111297A (pt) * 2000-05-30 2004-01-06 Santen Pharmaceutical Co Ltd Promotor de migração epitelial corneana
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR034635A1 (es) * 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
CN1612739A (zh) * 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CA2520028A1 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20050131224A1 (en) * 2003-12-15 2005-06-16 Cti Pet Systems, Inc. Method for preparing radiolabeled thymidine
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
EP1941883A1 (en) * 2007-01-08 2008-07-09 Universität Heidelberg Use of sodium blockers for an early therapy of obstructive lung diseases
EP2391209A4 (en) * 2009-01-27 2014-03-26 Teleflex Medical Inc Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
DK0981534T3 (da) * 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US6060327A (en) * 1997-05-14 2000-05-09 Keensense, Inc. Molecular wire injection sensors
GB2342176B (en) * 1998-02-02 2001-05-02 Signature Bioscience Inc Method and apparatus for detecting molecular binding events

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923143A (zh) * 2014-04-10 2014-07-16 江西科技师范大学 一种合成双核苷四磷酸以及p2,p3-（双卤代）亚甲基双核苷四磷酸的方法

Also Published As

Publication number Publication date
US6323187B1 (en) 2001-11-27
ATE232733T1 (de) 2003-03-15
JP2002516273A (ja) 2002-06-04
EP1087777A2 (en) 2001-04-04
JP4633927B2 (ja) 2011-02-16
AU746750B2 (en) 2002-05-02
DE69905464T2 (de) 2004-01-15
DE69905464D1 (de) 2003-03-27
AU4083999A (en) 1999-12-13
EP1087777B1 (en) 2003-02-19
WO1999061012A2 (en) 1999-12-02
WO1999061012A3 (en) 2000-02-10
CA2332540A1 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
CN1301168A (zh) 治疗性二核苷酸和衍生物
JP7561870B2 (ja) ヌクレオシド類似体またはヌクレオシド類似体を含有する併用製剤の抗ウイルスにおける使用
DE69822482T2 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
CN1229114C (zh) 用三磷酸尿苷和相关化合物治疗纤毛运动障碍的方法
US5763447A (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
US20120015898A1 (en) Compounds and methods for treatment of sickle cell disease or complications associated therewith
NO326718B1 (no) Dinukleotider og farmasøytiske preparater omfattende slike, og anvendelser derav for fremstilling av medikamenter.
CN1115152C (zh) 用尿苷三磷酸及相关化合物治疗支气管炎的方法
JP2873313B2 (ja) 化合物
JP2000505447A (ja) ウリジン三リン酸及び関連化合物で中耳炎を治療する方法
WO2022068923A1 (zh) 血管生成素样3(ANGPTL3)的siRNA及其用途
US20010011079A1 (en) Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US20090111774A1 (en) Pmea lipid conjugates
CN116217579B (zh) 一种巴拉苏酰胺衍生物及其在制备治疗急性肺损伤药物中的应用
CN113318231A (zh) 一种4-氨基喹啉类化合物的应用
MXPA00011495A (en) Therapeutic dinucleotide and derivatives
CN119970747B (zh) 化合物c692-0434的抗骨关节炎用途
CN104324044A (zh) 制造核苷四磷酸类似物的方法
CN118510784A (zh) 作为TLR4调节剂用于治疗免疫疾病的衍生物的5-氨基六氢-6,7,8-三羟基-3H-噁唑并[3,4-a]吡啶-3-酮衍生物
CN121177281A (zh) 山奈酚在制备用于促进纤毛生长的药物中的应用
CN116693583A (zh) 一种附子苷类似物及其制备方法和用途
HK1021136A (en) Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients
CN101874804A (zh) 抗耐药性的抗生素
HK1022099A (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication